Toronto, ON, January 23, 2007 – A team of Canadian researchers, lead by Dr. Susan George and Dr. Brian O'Dowd at the Centre for Addiction and Mental Health
(CAMH), discovered a distinct dopamine signalling complex in the brain. Composed of two different types of dopamine receptors,
this novel target may have a significant role in understanding and treating schizophrenia.
Published in the Proceedings of the National Academy of Sciences USA (Rashid et al., 2007), this important discovery demonstrates the existence of a Gq/11-coupled signalling unit that triggers a calcium signal, which
is turned on by stimulating D1 and D2 dopamine receptors. Unlike other dopamine receptors, this novel unit will only create
brain signals when both receptors are stimulated at the same time.
Using animal models. Drs. George and O’Dowd and their team identified this complex by its unique reaction to dopamine or specific
drug triggers. Strikingly, stimulating this target with dopamine or specific drugs triggered a rise in calcium in the brain. As
calcium has a profound effect on almost all brain function, this rise in calcium causes a cascade of events in the brain. This
is the first time that a direct connection between dopamine and calcium signals has been reported.
“This distinct unit provides a novel signalling pathway through which dopamine can impact the function of brain cells”, said
Dr. George. “This is significant because signalling through calcium release is a major mechanism regulating many important
functions in the brain and we have provided the first direct mechanism by which dopamine can activate a calcium signal.”
This data has significant implications for schizophrenia. Research tells us that people with schizophrenia may have disordered
calcium signals, and the major treatments for this disease target the dopamine system. Drs. George and O’Dowd state, "our
data links these two pieces of evidence, creating better understanding of the disease and opening the door for a new generation
of highly specific drugs that may help alleviate the devastating symptoms of schizophrenia."
The research was funded by grants from the NIH National Institute on Drug Abuse and the Canadian Institutes for Health Research.
For more information on this study view the abstract online here: D1–D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum.
The Centre for Addiction and Mental Health (CAMH) is one of the largest addiction and mental health organizations in North
America and Canada's leading mental health and addiction teaching hospital. CAMH is a Pan American Health Organization and
World Health Organization Collaborating Centre, and is fully affiliated with the University of Toronto. CAMH combines clinical
care, research, policy, education and health promotion to improve the lives of people impacted by mental health and addiction
For more information or to schedule interviews please contact Michael Torres, Media Relations Coordinator, CAMH at (416) 595-6015.